Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System - Seite 2
Forward-Looking Statements
Statements contained in this release that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include
statements regarding the intent, belief or current expectations of Chembio and its management with respect to obtaining an EUA for a COVID-19 antibody system. Such statements reflect management's
current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including, but not limited to: Chembio’s research, development and commercialization efforts may not result in its
successfully and timely developing and commercializing a COVID-19 antibody system; Chembio may be unable to anticipate or respond to changes in FDA regulatory requirements with respect to its
proposed COVID-19 antibody system, or otherwise may be unable to obtain or maintain an EUA, or other necessary regulatory approvals, for its COVID-19 antigen system; potential customers may not
adopt antibody systems to the extent expected by Chembio; and Chembio may not be able to compete successfully with other companies that have developed, or develop in the future, COVID-19 antibody
detection systems, some of which companies have substantially greater resources than Chembio. Chembio undertakes no obligation to publicly update forward-looking statements in this release to
reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to the forward-looking statements or the occurrence of unanticipated
events. Factors that may impact Chembio's success are more fully disclosed in Chembio's public filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for
the fiscal year ended December 31, 2019 and its subsequent Quarterly Reports on Form 10-Q, particularly under the heading “Risk Factors.” Readers should interpret many of the risks identified in
these reports as being heightened as a result of the ongoing and numerous adverse impacts of the COVID-19 pandemic.